Shanghai Shengdi Pharmaceutical Co., Ltd

This phase 3 trial tests a new contrast agent called HRS-9231 for MRI scans of the brain and spine. The goal is to see if it works as well as the standard contrast agent (gadobutrol) at making lesions visible. About 250 adults with known or suspected brain or spine lesions will r…

This study tests a new contrast agent called HRS-9231 for MRI scans of body parts (excluding the brain and spine). The goal is to see if it makes abnormal blood vessels or lesions show up as clearly as a standard contrast agent. About 309 adults who already need a contrast MRI ar…